WO1999012964A3 - Kay, nouvelle proteine du systeme immunitaire - Google Patents
Kay, nouvelle proteine du systeme immunitaire Download PDFInfo
- Publication number
- WO1999012964A3 WO1999012964A3 PCT/US1998/019037 US9819037W WO9912964A3 WO 1999012964 A3 WO1999012964 A3 WO 1999012964A3 US 9819037 W US9819037 W US 9819037W WO 9912964 A3 WO9912964 A3 WO 9912964A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- kay
- immune system
- system protein
- novel immune
- novel
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/525—Tumour necrosis factor [TNF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Transplantation (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Priority Applications (13)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002303424A CA2303424A1 (fr) | 1997-09-12 | 1998-09-11 | Kay, nouvelle proteine du systeme immunitaire |
HU0004034A HUP0004034A3 (en) | 1997-09-12 | 1998-09-11 | Kay - a novel immune system protein |
SK353-2000A SK3532000A3 (en) | 1997-09-12 | 1998-09-11 | Dna sequence coding for kay ligand, method for the preparation of kay ligand, pharmaceutical composition containing said ligand and the use thereof |
IL13448098A IL134480A0 (en) | 1997-09-12 | 1998-09-11 | Kay - an immune system protein and dna sequences encoding the same |
AU93152/98A AU9315298A (en) | 1997-09-12 | 1998-09-11 | Kay - a novel immune system protein |
JP2000510769A JP2001515711A (ja) | 1997-09-12 | 1998-09-11 | Kay−新規の免疫系タンパク質 |
EA200000311A EA200000311A1 (ru) | 1997-09-12 | 1998-09-11 | Новый белок иммунной системы - кау |
EP98946052A EP1012270A2 (fr) | 1997-09-12 | 1998-09-11 | Kay, nouvelle proteine du systeme immunitaire |
BR9812433-1A BR9812433A (pt) | 1997-09-12 | 1998-09-11 | Kay- uma proteìna do sistema de imunização |
EEP200000148A EE200000148A (et) | 1997-09-12 | 1998-09-11 | Kay - uus immuunsüsteemi valk |
KR1020007002576A KR20010023892A (ko) | 1997-09-12 | 1998-09-11 | Kay-신규 면역계 단백질 |
IS5375A IS5375A (is) | 1997-09-12 | 2000-02-11 | KAY-nýstárlegt ónæmisprótín |
NO20001240A NO20001240L (no) | 1997-09-12 | 2000-03-09 | Kay-A immunsystemprotein |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US5878697P | 1997-09-12 | 1997-09-12 | |
US60/058,786 | 1997-09-12 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1999012964A2 WO1999012964A2 (fr) | 1999-03-18 |
WO1999012964A3 true WO1999012964A3 (fr) | 1999-05-27 |
Family
ID=22018915
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1998/019037 WO1999012964A2 (fr) | 1997-09-12 | 1998-09-11 | Kay, nouvelle proteine du systeme immunitaire |
Country Status (17)
Country | Link |
---|---|
EP (1) | EP1012270A2 (fr) |
JP (1) | JP2001515711A (fr) |
KR (1) | KR20010023892A (fr) |
CN (1) | CN1269832A (fr) |
AU (1) | AU9315298A (fr) |
BR (1) | BR9812433A (fr) |
CA (1) | CA2303424A1 (fr) |
EA (1) | EA200000311A1 (fr) |
EE (1) | EE200000148A (fr) |
HU (1) | HUP0004034A3 (fr) |
IL (1) | IL134480A0 (fr) |
IS (1) | IS5375A (fr) |
NO (1) | NO20001240L (fr) |
PL (1) | PL339740A1 (fr) |
SK (1) | SK3532000A3 (fr) |
TR (1) | TR200000654T2 (fr) |
WO (1) | WO1999012964A2 (fr) |
Families Citing this family (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6812327B1 (en) | 1996-10-25 | 2004-11-02 | Human Genome Sciences, Inc. | Neutrokine-alpha polypeptides |
WO1999026463A2 (fr) * | 1997-11-26 | 1999-06-03 | Eli Lilly And Company | Gene de la famille des ligand tnf |
WO1999033980A2 (fr) * | 1997-12-30 | 1999-07-08 | Chiron Corporation | Membres de familles de tnf et de tnfr |
US6297367B1 (en) | 1997-12-30 | 2001-10-02 | Chiron Corporation | Polynucleotide encoding TNFL1 |
US7488590B2 (en) | 1998-10-23 | 2009-02-10 | Amgen Inc. | Modified peptides as therapeutic agents |
GB9828628D0 (en) | 1998-12-23 | 1999-02-17 | Glaxo Group Ltd | Novel ligand |
US7833529B1 (en) | 1999-01-07 | 2010-11-16 | Zymogenetics, Inc. | Methods for inhibiting B lymphocyte proliferation with soluble ztnf4 receptor |
EP2319527A3 (fr) | 1999-01-25 | 2011-10-12 | Biogen Idec MA Inc. | BAFF, ses inhibiteurs et leur utilisation pour moduler la réponse immunitaire des cellules B et des immunoglobulines |
US20030095967A1 (en) | 1999-01-25 | 2003-05-22 | Mackay Fabienne | BAFF, inhibitors thereof and their use in the modulation of B-cell response and treatment of autoimmune disorders |
US6475986B1 (en) * | 1999-02-02 | 2002-11-05 | Research Development Foundation | Uses of THANK, a TNF homologue that activates apoptosis |
JP2003526330A (ja) * | 1999-02-23 | 2003-09-09 | ヒューマン ジノーム サイエンシーズ, インコーポレイテッド | ニュートロカイン−αおよびニュートロカイン−αスプライス改変体 |
US20030022233A1 (en) | 1999-04-30 | 2003-01-30 | Raymond G. Goodwin | Methods of use of the taci/taci-l interaction |
WO2000068378A1 (fr) * | 1999-05-06 | 2000-11-16 | National Jewish Medical And Research Center | Molecules d'acide nucleique, proteines et recepteurs tall-1, et procedes d'utilisation |
GEP20053685B (en) * | 1999-08-17 | 2005-12-12 | Biogen Inc | BAFF Receptor (BCMA), an Immunoregulatory Agent |
UA74798C2 (uk) | 1999-10-06 | 2006-02-15 | Байоджен Айдек Ма Інк. | Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами |
AU3495301A (en) | 2000-02-11 | 2001-08-20 | Biogen Inc | Heterologous polypeptide of the tnf family |
CA2396793A1 (fr) | 2000-02-16 | 2001-08-23 | Genentech, Inc. | Utilisation d'agonistes ou d'antagonistes pour moduler l'activite de molecules associees au tnf |
MXPA02011130A (es) | 2000-05-12 | 2003-03-10 | Amgen Inc | Metodos y composiciones de materia que se refieren a april/g70, bcma, blys/agp-3, y taci. |
US7220840B2 (en) | 2000-06-16 | 2007-05-22 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to B lymphocyte stimulator protein |
PT2281843T (pt) | 2000-06-16 | 2017-01-02 | Human Genome Sciences Inc | Anticorpos que se ligam imunoespecificamente a blys |
CA2419661A1 (fr) * | 2000-08-15 | 2002-03-07 | Guo-Liang Yu | Neutrokine-alpha et variant d'epissage de neutrokine-alpha |
AU2001288301A1 (en) | 2000-08-18 | 2002-03-04 | Human Genome Sciences, Inc. | Binding polypeptides and methods based thereon |
UA83458C2 (uk) | 2000-09-18 | 2008-07-25 | Байоджен Айдек Ма Інк. | Виділений поліпептид baff-r (рецептор фактора активації в-клітин сімейства tnf) |
EA010435B1 (ru) | 2001-05-11 | 2008-08-29 | Амген, Инк. | Связывающиеся с tall-1 молекулы и их применение |
AR035119A1 (es) | 2001-08-16 | 2004-04-14 | Lilly Co Eli | Anticuerpos humanos antagonistas anti-htnfsf13b |
AU2004233164B2 (en) | 2003-03-28 | 2009-10-08 | Biogen Ma Inc. | Truncated BAFF receptors |
KR20060027801A (ko) | 2003-06-05 | 2006-03-28 | 제넨테크, 인크. | B 세포 장애에 대한 조합 요법 |
CN1897966A (zh) | 2003-10-20 | 2007-01-17 | 比奥根艾迪克Ma公司 | 使用baff拮抗剂的治疗方法 |
CA2554526A1 (fr) * | 2004-01-29 | 2005-08-18 | Genentech, Inc. | Variants du domaine extracellulaire de bcma et utilisations de ceux-ci |
US20060110387A1 (en) | 2004-10-05 | 2006-05-25 | Genentech, Inc. | Method for treating vasculitis |
EP2332563A3 (fr) | 2004-10-13 | 2013-03-13 | The Washington University | Utilisation de BAFF pour traiter la sepsie |
JP2008525002A (ja) | 2004-12-23 | 2008-07-17 | ラボラトワール セローノ ソシエテ アノニム | Bcmaポリペプチド及びその使用 |
CN101262876A (zh) | 2005-08-09 | 2008-09-10 | 酶遗传学股份有限公司 | 用taci-ig融合分子治疗b细胞恶性肿瘤的方法 |
US8808696B2 (en) | 2005-08-09 | 2014-08-19 | Ares Trading S.A. | Methods for the treatment and prevention of abnormal cell proliferation using TACI-fusion molecules |
US9168286B2 (en) | 2005-10-13 | 2015-10-27 | Human Genome Sciences, Inc. | Methods and compositions for use in treatment of patients with autoantibody positive disease |
MY149159A (en) | 2005-11-15 | 2013-07-31 | Hoffmann La Roche | Method for treating joint damage |
WO2007062090A2 (fr) | 2005-11-23 | 2007-05-31 | Genentech, Inc. | Procedes et compositions lies a des analyses de lymphocytes b |
US8211649B2 (en) | 2006-03-31 | 2012-07-03 | Human Genome Sciences, Inc. | Methods of diagnosing and prognosing hodgkin's lymphoma |
EA015342B1 (ru) | 2006-05-15 | 2011-06-30 | Арес Трейдинг С.А. | Способы лечения аутоиммунных заболеваний с использованием слитой молекулы taci-ig |
WO2010075249A2 (fr) | 2008-12-22 | 2010-07-01 | Genentech, Inc. | Méthode de traitement de la polyarthrite rhumatoïde avec des antagonistes de cellules b |
MX353186B (es) | 2009-09-03 | 2018-01-05 | Genentech Inc | Metodos para el tratamiento, diagnosis y monitoreo de artritis reumatoide. |
RU2013140975A (ru) | 2011-02-28 | 2015-04-10 | Дженентек, Инк. | Биологические маркеры и способы прогнозирования восприимчивости к антагонистам в-клеток |
WO2014122144A1 (fr) | 2013-02-05 | 2014-08-14 | Engmab Ag | Anticorps bispécifiques anti-cd3ɛ et bcma |
JOP20140087B1 (ar) | 2013-03-13 | 2021-08-17 | Amgen Inc | بروتينات مخصصة ل baff و b7rp1 وإستخداماتها |
US9458246B2 (en) | 2013-03-13 | 2016-10-04 | Amgen Inc. | Proteins specific for BAFF and B7RP1 |
US10138251B2 (en) | 2014-04-11 | 2018-11-27 | Boehringer Ingelheim International Gmbh | Spiro[3H-indole-3,2′-pyrrolidin]-2(1H)-one compounds and derivatives as MDM2-P53 inhibitors |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994018325A1 (fr) * | 1993-02-03 | 1994-08-18 | N.V. Innogenetics S.A. | Muteines de tnf-alpha et leur procede de preparation |
WO1996040774A1 (fr) * | 1995-06-07 | 1996-12-19 | Biogen, Inc. | Complexes de lymphotoxines modifiees utilises comme preparations pharmaceutiques |
WO1998018921A1 (fr) * | 1996-10-25 | 1998-05-07 | Human Genome Sciences, Inc. | Neutrokine alpha |
WO1998027114A2 (fr) * | 1996-12-17 | 1998-06-25 | Schering Corporation | Antigenes de surface mammaliens et reactifs associes |
EP0869180A1 (fr) * | 1997-04-02 | 1998-10-07 | Smithkline Beecham Corporation | Un homologue de TNF, TL5 |
-
1998
- 1998-09-11 CN CN98809023A patent/CN1269832A/zh active Pending
- 1998-09-11 JP JP2000510769A patent/JP2001515711A/ja not_active Withdrawn
- 1998-09-11 EP EP98946052A patent/EP1012270A2/fr not_active Withdrawn
- 1998-09-11 WO PCT/US1998/019037 patent/WO1999012964A2/fr not_active Application Discontinuation
- 1998-09-11 IL IL13448098A patent/IL134480A0/xx unknown
- 1998-09-11 KR KR1020007002576A patent/KR20010023892A/ko not_active Application Discontinuation
- 1998-09-11 TR TR2000/00654T patent/TR200000654T2/xx unknown
- 1998-09-11 BR BR9812433-1A patent/BR9812433A/pt not_active IP Right Cessation
- 1998-09-11 HU HU0004034A patent/HUP0004034A3/hu unknown
- 1998-09-11 SK SK353-2000A patent/SK3532000A3/sk unknown
- 1998-09-11 EE EEP200000148A patent/EE200000148A/xx unknown
- 1998-09-11 AU AU93152/98A patent/AU9315298A/en not_active Abandoned
- 1998-09-11 EA EA200000311A patent/EA200000311A1/ru unknown
- 1998-09-11 PL PL98339740A patent/PL339740A1/xx not_active Application Discontinuation
- 1998-09-11 CA CA002303424A patent/CA2303424A1/fr not_active Abandoned
-
2000
- 2000-02-11 IS IS5375A patent/IS5375A/is unknown
- 2000-03-09 NO NO20001240A patent/NO20001240L/no not_active Application Discontinuation
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994018325A1 (fr) * | 1993-02-03 | 1994-08-18 | N.V. Innogenetics S.A. | Muteines de tnf-alpha et leur procede de preparation |
WO1996040774A1 (fr) * | 1995-06-07 | 1996-12-19 | Biogen, Inc. | Complexes de lymphotoxines modifiees utilises comme preparations pharmaceutiques |
WO1998018921A1 (fr) * | 1996-10-25 | 1998-05-07 | Human Genome Sciences, Inc. | Neutrokine alpha |
WO1998027114A2 (fr) * | 1996-12-17 | 1998-06-25 | Schering Corporation | Antigenes de surface mammaliens et reactifs associes |
EP0869180A1 (fr) * | 1997-04-02 | 1998-10-07 | Smithkline Beecham Corporation | Un homologue de TNF, TL5 |
Also Published As
Publication number | Publication date |
---|---|
EA200000311A1 (ru) | 2000-10-30 |
HUP0004034A3 (en) | 2002-08-28 |
JP2001515711A (ja) | 2001-09-25 |
CA2303424A1 (fr) | 1999-03-18 |
EE200000148A (et) | 2001-02-15 |
WO1999012964A2 (fr) | 1999-03-18 |
CN1269832A (zh) | 2000-10-11 |
SK3532000A3 (en) | 2001-12-03 |
NO20001240D0 (no) | 2000-03-09 |
KR20010023892A (ko) | 2001-03-26 |
IS5375A (is) | 2000-02-11 |
IL134480A0 (en) | 2001-04-30 |
AU9315298A (en) | 1999-03-29 |
NO20001240L (no) | 2000-05-10 |
HUP0004034A2 (en) | 2001-03-28 |
TR200000654T2 (tr) | 2000-07-21 |
EP1012270A2 (fr) | 2000-06-28 |
BR9812433A (pt) | 2000-09-26 |
PL339740A1 (en) | 2001-01-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1999012964A3 (fr) | Kay, nouvelle proteine du systeme immunitaire | |
WO1999012965A3 (fr) | Nouveaux ligands de la famille des tnf | |
EP1591530B8 (fr) | Ligand associé au facteur de nécrose tumorale | |
AU1102399A (en) | Human tumor necrosis factor receptor-like proteins tr11, tr11sv1, and tr11sv2 | |
ZA947122B (en) | Drug binding protein. | |
AU2526797A (en) | Stimulation of immune response with low doses of interleukin-2 | |
AU9597398A (en) | Increasing the digestibility of food proteins by thioredoxin reduction | |
AU7705198A (en) | Human tumor necrosis factor receptor tr10 | |
AU7705098A (en) | Human tumor necrosis factor receptor-like protein 8 | |
AU7624598A (en) | 1,4-diazabicyclo (2.2.2) Oct-2-ylmethyl derivatives, their preparation and the rapeutic application | |
AU5389096A (en) | Human hematopoietic-specific protein | |
AU3003095A (en) | Proteins associated with tumor necrosis factor receptor | |
AU1541699A (en) | Human tumor necrosis factor-r2-like proteins | |
AU7495796A (en) | Novel oligopeptides, the preparation and use thereof | |
AU1750997A (en) | Obesity protein formulations | |
AU1705197A (en) | Obesity protein formulations | |
AU2243997A (en) | Obesity protein formulations | |
AU5358894A (en) | Recombinant alliinase, its preparation and pharmaceutical compositions comprising it | |
AU5777696A (en) | Candida heat shock protein, cdna and uses thereof | |
AU1747297A (en) | Obesity protein formulations | |
AU1693995A (en) | Phosphacan, nucleic acids encoding thereof and antibodies thereto | |
WO1998018818A3 (fr) | Nouveaux inhibiteurs de l'hepatite b | |
AU7478098A (en) | Methods of treatment using nbs-1, antibodies and proteins thereto, and uses of the antibodies | |
AU6569998A (en) | Obesity protein formulations | |
AU4483597A (en) | Novel tumor proteins |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 134480 Country of ref document: IL Ref document number: 98809023.6 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 93152/98 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: PV2000-867 Country of ref document: CZ Ref document number: 2000/00654 Country of ref document: TR |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/A/2000/002410 Country of ref document: MX |
|
ENP | Entry into the national phase |
Ref document number: 2303424 Country of ref document: CA Ref document number: 2303424 Country of ref document: CA Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020007002576 Country of ref document: KR Ref document number: 3532000 Country of ref document: SK |
|
ENP | Entry into the national phase |
Ref document number: 2000 510769 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1998946052 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 503849 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200000311 Country of ref document: EA |
|
WWP | Wipo information: published in national office |
Ref document number: 1998946052 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: PV2000-867 Country of ref document: CZ |
|
WWP | Wipo information: published in national office |
Ref document number: 1020007002576 Country of ref document: KR |
|
WWR | Wipo information: refused in national office |
Ref document number: PV2000-867 Country of ref document: CZ |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1998946052 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1020007002576 Country of ref document: KR |